126 related articles for article (PubMed ID: 23811255)
1. Capping the gastric acid pocket to reduce postprandial acid gastroesophageal reflux.
Sifrim D; Penagini R
Clin Gastroenterol Hepatol; 2013 Dec; 11(12):1592-4. PubMed ID: 23811255
[No Abstract] [Full Text] [Related]
2. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease.
Rohof WO; Bennink RJ; Smout AJ; Thomas E; Boeckxstaens GE
Clin Gastroenterol Hepatol; 2013 Dec; 11(12):1585-91; quiz e90. PubMed ID: 23669304
[TBL] [Abstract][Full Text] [Related]
3. Raft-forming agents: antireflux formulations.
Kapadia CJ; Mane VB
Drug Dev Ind Pharm; 2007 Dec; 33(12):1350-61. PubMed ID: 18097809
[TBL] [Abstract][Full Text] [Related]
4. A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms.
Giannini EG; Zentilin P; Dulbecco P; Iiritano E; Bilardi C; Savarino E; Mansi C; Savarino V
Dig Dis Sci; 2006 Nov; 51(11):1904-9. PubMed ID: 16977507
[TBL] [Abstract][Full Text] [Related]
5. [Diagnostic value of alginate test in gastroesophageal reflux disease].
Bordin DS; Masharova AA; Droxzdov VN; Firsova LD; Kozhurina TS
Eksp Klin Gastroenterol; 2010; (12):102-7. PubMed ID: 21560632
[TBL] [Abstract][Full Text] [Related]
6. Alginate-antacid combinations: raft formation and gastric retention studies.
Hampson FC; Jolliffe IG; Bakhtyari A; Taylor G; Sykes J; Johnstone LM; Dettmar PW
Drug Dev Ind Pharm; 2010 May; 36(5):614-23. PubMed ID: 19925256
[TBL] [Abstract][Full Text] [Related]
7. [The acid pocket as the pathogenic basis and therapeutic target in gastroesophageal reflux disease].
Bordin DS
Ter Arkh; 2014; 86(2):76-81. PubMed ID: 24772513
[TBL] [Abstract][Full Text] [Related]
8. Algitec: an illogical combination?
Drug Ther Bull; 1990 Sep; 28(19):76. PubMed ID: 2131223
[No Abstract] [Full Text] [Related]
9. [Stenosing gastric laryngitis in infancy].
Hennig A; Neumann A; Schultz-Coulon HJ
HNO; 2004 Apr; 52(4):352-5. PubMed ID: 15024469
[TBL] [Abstract][Full Text] [Related]
10. [From the results of the "MEGRE" study to the "Society against heartburn" project].
Bordin DS; Masharova AA; Lazebnik LB
Eksp Klin Gastroenterol; 2011; (2):15-21. PubMed ID: 21560639
[TBL] [Abstract][Full Text] [Related]
11. Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis.
Leiman DA; Riff BP; Morgan S; Metz DC; Falk GW; French B; Umscheid CA; Lewis JD
Dis Esophagus; 2017 May; 30(5):1-9. PubMed ID: 28375448
[TBL] [Abstract][Full Text] [Related]
12. Alginate therapy is effective treatment for gastroesophageal reflux disease symptoms: a systematic review and meta-analysis.
Leiman DA; Riff BP; Morgan S; Metz DC; Falk GW; French B; Umscheid CA; Lewis JD
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27671545
[TBL] [Abstract][Full Text] [Related]
13. [Alginate-raft preparations in the treatment of acid reflux and heartburn (literature review)].
Mandel KG; Deggi BP; Brodi DA; Jeykobi GI
Eksp Klin Gastroenterol; 2008; (4):64-77. PubMed ID: 19145905
[No Abstract] [Full Text] [Related]
14. Changing clinical perspectives toward gastroesophageal reflux.
Krueger KJ; DiPalma JA
South Med J; 1996 May; 89(5):548-50. PubMed ID: 8638191
[No Abstract] [Full Text] [Related]
15. GERD: Alginate rafts localize to the acid pocket and reduce acid reflux in GERD.
Leake I
Nat Rev Gastroenterol Hepatol; 2013 Jul; 10(7):386. PubMed ID: 23712315
[No Abstract] [Full Text] [Related]
16. [Estimation of efficiency of alginate-raft barrier in treatment of gastroesophageal reflux disease].
Bordin DS; Masharova AA; Firsova LD; Kozhurina TS; Safonova OV
Eksp Klin Gastroenterol; 2008; (6):77-81. PubMed ID: 19334430
[No Abstract] [Full Text] [Related]
17. The role of an alginate suspension on pepsin and bile acids - key aggressors in the gastric refluxate. Does this have implications for the treatment of gastro-oesophageal reflux disease?
Strugala V; Avis J; Jolliffe IG; Johnstone LM; Dettmar PW
J Pharm Pharmacol; 2009 Aug; 61(8):1021-8. PubMed ID: 19703345
[TBL] [Abstract][Full Text] [Related]
18. [Gastroesophageal reflux disease during pregnancy].
Elokhina TB; Tiutiunnik VL
Eksp Klin Gastroenterol; 2009; (3):93-7. PubMed ID: 19928006
[No Abstract] [Full Text] [Related]
19. [Alginate-containing preparation gaviscon for patients with gastroesophaginal reflux complicated with chronic pancreatitis: pathogenetic substantiation of clinical use prospects].
Uspenskiĭ IuP; Pakhomova IG; Bubiakina VN
Eksp Klin Gastroenterol; 2008; (1):96-101. PubMed ID: 19145860
[No Abstract] [Full Text] [Related]
20. Co-prescription of alginate based formulations & proton pump inhibitors (PPIs) in gastro-oesophageal reflux disease: time for rethink?
Davis S; Kshirsagar NA
Indian J Med Res; 2006 Apr; 123(4):493-6. PubMed ID: 16783039
[No Abstract] [Full Text] [Related]
[Next] [New Search]
